Hazard Function Analysis of Recurrence in Patients with Curatively Resected Lung Cancer: Results from the Japanese Lung Cancer Registry in 2010
Authors:
- Yoshikane YamauchiYoshikane Yamauchi
- Masafumi KawamuraMKMasafumi Kawamura
- Jiro OkamiJOJiro Okami
- Yasushi ShintaniYasushi Shintani
- Hiroyuki ItoHIHiroyuki Ito
- Takashi OhtsukaTOTakashi Ohtsuka
- Shinichi ToyookaSTShinichi Toyooka
- Takeshi MoriTMTakeshi Mori
- Shun-Ichi WatanabeSWShun-Ichi Watanabe
- Hisao AsamuraHAHisao Asamura
- Masayuki ChidaMCMasayuki Chida
- Shunsuke EndoSEShunsuke Endo
Open Access
Abstract
To optimize postoperative surveillance of lung cancer patients, we investigated the hazard function of tumor recurrence in patients with completely resected lung cancer. We analyzed the records of 12,897 patients in the 2010 Japanese Joint Committee of Lung Cancer Registry who underwent lobectomy to completely resect pathological stage I–III lung cancer. The risk of postoperative recurrence was determined using a cause-specific hazard function. The hazard function for recurrence exhibited a peak at approximately 9 months after surgery, followed by a tapered plateau-like tail extending to 60 months. The peak risk for intrathoracic recurrence was approximately two-fold higher compared with that of extrathoracic recurrence. Subgroup analysis showed that patients with stage IIIA adenocarcinoma had a continuously higher risk of recurrence compared with patients with earlier-stage disease. However, the risk of recurrence in patients with squamous cell carcinoma was not significantly different compared with that more than 24 months after surgery, regardless of pathological stage. In conclusion, the characteristics of postoperative tumor recurrence hazard in a large cohort of lung cancer patients may be useful for determining the time after surgery at which patients are at the highest risk of tumor recurrence. This information may improve stage-related management of postoperative surveillance.Keywords
This publication has 38 references indexed in Scilit:
- Metastasis Dynamics for Non–Small-Cell Lung Cancer: Effect of Patient and Tumor-Related FactorsClinical Lung Cancer, 2013
- Results of Initial Low-Dose Computed Tomographic Screening for Lung CancerNew England Journal of Medicine, 2013
- Recurrence Dynamics for Non–Small-Cell Lung Cancer: Effect of Surgery on the Development of MetastasesJournal of Thoracic Oncology, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- International Ethical Guidelines for Epidemiological StudiesAmerican Journal of Epidemiology, 2009
- The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung CancerJournal of Thoracic Oncology, 2009
- A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung CancersJournal of Thoracic Oncology, 2008
- Development of Health Insurance Policy in JapanJournal of Health Politics, Policy and Law, 1982
- Kernel estimation of regression functions1979